{"id":"benralizumab-medi-563","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nasopharyngitis"},{"rate":null,"effect":"Upper respiratory tract infection"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Worsening asthma"}]},"_chembl":{"chemblId":"CHEMBL1742991","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Benralizumab targets the IL-5 receptor alpha (CD125) expressed on eosinophils and basophils, blocking IL-5 signaling and triggering antibody-dependent cell-mediated cytotoxicity (ADCC) to eliminate these cells. This mechanism reduces eosinophilic inflammation in the airways and tissues, making it effective for eosinophil-driven inflammatory diseases. By directly targeting the IL-5 receptor rather than IL-5 itself, benralizumab achieves rapid and sustained eosinophil depletion.","oneSentence":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:03:56.288Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Moderate-to-severe eosinophilic asthma"},{"name":"Severe eosinophilic granulomatosis with polyangiitis (EGPA)"}]},"trialDetails":[{"nctId":"NCT06512883","phase":"PHASE3","title":"A Trial to Investigate Benralizumab in Children With Eosinophilic Diseases","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-04-17","conditions":"Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilia Syndrome (HES)","enrollment":14},{"nctId":"NCT06862206","phase":"","title":"This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-11","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":1000},{"nctId":"NCT06750289","phase":"PHASE3","title":"Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-03-28","conditions":"Eosinophilic Asthma","enrollment":400},{"nctId":"NCT03953300","phase":"PHASE4","title":"Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-08","conditions":"Asthma","enrollment":75},{"nctId":"NCT05603845","phase":"","title":"Patient-Reported OUTcomes of Benralizumab in Real-World Use in Severe EosiNophilic Asthma Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-02-20","conditions":"Severe Asthma","enrollment":291},{"nctId":"NCT07214753","phase":"","title":"A Real-life Observational Study in Severe Eosinophilic Asthma Adult Participant Treated With Benralizumab in Italy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-12-20","conditions":"Severe Eosinophilic Asthma","enrollment":335},{"nctId":"NCT05692180","phase":"PHASE3","title":"A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-04-05","conditions":"Asthma","enrollment":200},{"nctId":"NCT06427876","phase":"","title":"Fasenra Pediatric Japan Post-Marketing Study(PMS)","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-16","conditions":"Bronchial Asthma","enrollment":40},{"nctId":"NCT07444567","phase":"PHASE3","title":"Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra) and Benefit From Continued Treatment","status":"NOT_YET_RECRUITING","sponsor":"AstraZeneca","startDate":"2026-03-27","conditions":"Asthma, Eosinophilic Granulomatosis With Polyangiitis (EGPA), Hypereosinophilic Syndrome (HES)","enrollment":230},{"nctId":"NCT06422078","phase":"","title":"A Non-interventional, Prospective Study With Benralizumab","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-07-25","conditions":"Asthma, Bronchial","enrollment":300},{"nctId":"NCT04157335","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab in Patient With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps (ORCHID)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-11-25","conditions":"Nasal Polyposis, Eosinophilic Chronic Rhinosinusitis","enrollment":295},{"nctId":"NCT04191304","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of Benralizumab in Patients With Hypereosinophilic Syndrome (HES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2020-07-20","conditions":"Hypereosinophilic Syndrome","enrollment":134},{"nctId":"NCT05091333","phase":"","title":"FASENRA Regulatory Postmarketing Surveillance in Korea","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-03-11","conditions":"Asthma, EGPA(Eosinophilic Granulomatosis With Polyangiitis)","enrollment":51},{"nctId":"NCT04157348","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-29","conditions":"Eosinophilic Granulomatous Vasculitis","enrollment":140},{"nctId":"NCT06477653","phase":"PHASE2","title":"Dupilumab as Add-On Therapy for Hypereosinophilic Syndrome With Partial Clinical Response to Eosinophil-Depleting Biologic Agents","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-02-05","conditions":"Hypereosinophilic Syndrome","enrollment":30},{"nctId":"NCT07159295","phase":"","title":"Study in Portuguese Hospitals to Describe Patient Characteristics, Treatment Patterns and Outcomes","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-08-10","conditions":"Severe Asthma","enrollment":74},{"nctId":"NCT07218172","phase":"","title":"Characterization and Clinical Outcomes of Severe Asthma Patients in Israel Treated With Benralizumab (SAIL-B)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2025-03-24","conditions":"Severe Asthma","enrollment":197},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT06465485","phase":"PHASE3","title":"STEP: Phase IIIb Study of Benralizumab to Step-down Maintenance Therapy in Patients With Severe Eosinophilic Asthma","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2024-02-28","conditions":"Severe Eosinophilic Asthma","enrollment":504},{"nctId":"NCT03588546","phase":"","title":"FASENRA SCEI for Long-term Use","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-05-31","conditions":"Asthma","enrollment":653},{"nctId":"NCT03563066","phase":"PHASE2","title":"Effect of Benralizumab in Atopic Dermatitis","status":"COMPLETED","sponsor":"McMaster University","startDate":"2018-09-04","conditions":"Dermatitis, Atopic, Dermatitis, Eczema","enrollment":20},{"nctId":"NCT04053634","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With a History of Frequent Exacerbations","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-08-26","conditions":"Chronic Obstructive Pulmonary Disease","enrollment":689},{"nctId":"NCT06261567","phase":"","title":"A Retrospective Chart Review to Investigate Clinical Remission in Patients With Severe Asthma Treated With Biologics in the United Kingdom National Health Service","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2024-02-27","conditions":"Asthma","enrollment":415},{"nctId":"NCT03733535","phase":"NA","title":"Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dr. Grace Parraga","startDate":"2022-03-01","conditions":"Asthma; Eosinophilic","enrollment":29},{"nctId":"NCT04552288","phase":"PHASE2","title":"Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2020-09-16","conditions":"Solid Tumor, Solid Carcinoma, Solid Tumor, Adult","enrollment":51},{"nctId":"NCT05006573","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Patients With Non-cystic Fibrosis Bronchiectasis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-07-21","conditions":"Non-cystic Fibrosis Bronchiectasis","enrollment":100},{"nctId":"NCT05251909","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Patients With Eosinophilic Gastritis and/or Gastroenteritis (The HUDSON GI Study)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2022-01-18","conditions":"Eosinophilic Gastritis, Eosinophilic Gastroenteritis","enrollment":12},{"nctId":"NCT05440656","phase":"","title":"A Real World Study to Capture Clinical and Patient Centered Outcomes in Adults With Severe Eosinophilic Asthma Treated With Benralizumab.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-06-29","conditions":"Severe Eosinophilic Asthma","enrollment":152},{"nctId":"NCT04221802","phase":"","title":"Patient-reported Outcomes in Real-world Use of Benralizumab in Patients With Severe Eosinophilic Asthma in Belgium","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-12-23","conditions":"Severe Asthma","enrollment":76},{"nctId":"NCT04991805","phase":"","title":"Descriptive Study of the Incidence of Malignancy in Severe Asthma Patients Receiving Benralizumab and Other Biologic Therapy, a Post Authorization Safety Study","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-26","conditions":"Asthma, Neoplasms","enrollment":14000},{"nctId":"NCT05552508","phase":"PHASE4","title":"BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-10-11","conditions":"Asthma","enrollment":45},{"nctId":"NCT05734339","phase":"","title":"Patient-Reported Outcomes of Benralizumab in Real-World Use in Severe Eosinophilic Asthma Patients in Taiwan (BEAT)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2023-01-19","conditions":"Asthma","enrollment":43},{"nctId":"NCT06734884","phase":"PHASE2","title":"Interest of a Targeted Therapy for the Treatment of a Severe Form of Hypersensitivity to Drug (DRESS Syndrome)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2025-01-06","conditions":"DRESS Syndrome","enrollment":96},{"nctId":"NCT04159519","phase":"PHASE4","title":"A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-07-27","conditions":"Asthma, Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT05384938","phase":"PHASE4","title":"FAsenra Safety Trial in India","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-19","conditions":"In Adult Patients of Severe Asthma With Eosinophilic Phenotype in India","enrollment":139},{"nctId":"NCT04184284","phase":"","title":"Change in Patient-Reported Outcomes in Severe Eosinophilic Asthma Patients Treated With Benralizumab Under Real-life Conditions","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-11-15","conditions":"Asthma","enrollment":246},{"nctId":"NCT04612790","phase":"PHASE3","title":"A Study to Investigate the Use of Benralizumab in Patients With Bullous Pemphigoid.","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2021-03-31","conditions":"Bullous Pemphigoid","enrollment":67},{"nctId":"NCT03794999","phase":"","title":"Benralizumab Pregnancy Exposure Study","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2019-03-20","conditions":"Asthma","enrollment":299},{"nctId":"NCT04185012","phase":"PHASE3","title":"NAsal Polyps: Inflammatory & Molecular Phenotyping of Responders to Benralizumab","status":"COMPLETED","sponsor":"Humanitas Clinical and Research Center","startDate":"2020-02-24","conditions":"Nasal Polyps","enrollment":14},{"nctId":"NCT06239441","phase":"","title":"Effectiveness of Anti-IL-5/IL5R Inhibitors","status":"COMPLETED","sponsor":"Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal","startDate":"2021-02-16","conditions":"Severe Asthma","enrollment":108},{"nctId":"NCT05271526","phase":"","title":"Real World Evidence of Benralizumab in Eosinophilic Severe AsThma in Russia (BEST)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2022-05-16","conditions":"Severe Eosinophilic Asthma","enrollment":3},{"nctId":"NCT05966584","phase":"PHASE2","title":"A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer","status":"TERMINATED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-07-06","conditions":"Breast Cancer","enrollment":1},{"nctId":"NCT06385236","phase":"PHASE4","title":"Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping","status":"RECRUITING","sponsor":"University of California, San Diego","startDate":"2024-02-19","conditions":"Moderate to Severe Asthma","enrollment":120},{"nctId":"NCT06501807","phase":"NA","title":"BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Lille","startDate":"2024-09-02","conditions":"Rhinosinusitis Chronic, Nasal Polyps","enrollment":900},{"nctId":"NCT03833141","phase":"","title":"Patient Reported Outcomes in Adults With Severe Eosinophilic Asthma on Benralizumab.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-11-12","conditions":"Severe Eosinophilic Asthma","enrollment":170},{"nctId":"NCT06456450","phase":"","title":"Taiwan Severe Asthma Biologic Registry","status":"RECRUITING","sponsor":"Taichung Veterans General Hospital","startDate":"2023-11-11","conditions":"Pulmonary Disease, Asthma","enrollment":500},{"nctId":"NCT04565483","phase":"PHASE4","title":"Predictive Signature of Benralizumab Response","status":"RECRUITING","sponsor":"Nantes University Hospital","startDate":"2021-10-11","conditions":"Asthma; Eosinophilic, Severe Asthma","enrollment":220},{"nctId":"NCT04102800","phase":"PHASE4","title":"Benralizumab Exacerbation Study","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2019-09-30","conditions":"Asthma","enrollment":157},{"nctId":"NCT03186209","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-09-07","conditions":"Asthma","enrollment":695},{"nctId":"NCT06348173","phase":"","title":"Response and Remission to Treatment With Anti-IL5/IL5R Antagonists","status":"COMPLETED","sponsor":"Université de Montréal","startDate":"2023-06-01","conditions":"Asthma","enrollment":109},{"nctId":"NCT04612725","phase":"PHASE2","title":"A Study to Investigate the Use of Benralizumab in Patients With Chronic Spontaneous Urticaria Who Are Symptomatic Despite the Use of Antihistamines (ARROYO)","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-10-27","conditions":"Chronic Spontaneous Urticaria","enrollment":159},{"nctId":"NCT06288516","phase":"PHASE4","title":"BenRalizumab Effect on Airway Remodeling in Severe asTHma","status":"RECRUITING","sponsor":"Aristotle University Of Thessaloniki","startDate":"2024-03-01","conditions":"Asthma; Eosinophilic, Airway Remodeling","enrollment":45},{"nctId":"NCT03907137","phase":"","title":"Real World Study With Benralizumab in Severe Asthma in Switzerland","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-01-21","conditions":"Severe Eosinophilic Asthma","enrollment":79},{"nctId":"NCT05270278","phase":"","title":"Characteristics of Type 2- High Inflammatory Endotype of Asthma Using New Biomarkers From Peripheral Blood and Exhaled Air and Its Effect on the Outcome of Therapy","status":"COMPLETED","sponsor":"Value Outcomes Ltd.","startDate":"2022-08-16","conditions":"Asthma; Eosinophilic, Asthma Chronic, Bronchial Asthma","enrollment":89},{"nctId":"NCT04365205","phase":"","title":"Effect of Benralizumab on Airway Remodeling in Asthma","status":"UNKNOWN","sponsor":"University Hospital, Bordeaux","startDate":"2020-09-23","conditions":"Asthma","enrollment":60},{"nctId":"NCT04098718","phase":"PHASE2","title":"Acute Exacerbations Treated With BenRAlizumab (The ABRA Study)","status":"UNKNOWN","sponsor":"University of Oxford","startDate":"2021-03-29","conditions":"Asthma, COPD","enrollment":158},{"nctId":"NCT05528913","phase":"PHASE2","title":"Benralizumab in Chronic Prurigo - Investigating Clinical Efficacy (BICPIC)","status":"WITHDRAWN","sponsor":"Charite University, Berlin, Germany","startDate":"2023-10","conditions":"Chronic Prurigo","enrollment":""},{"nctId":"NCT05972213","phase":"","title":"Phenotypic and Functional Characterization of Neutrophils and Eosinophils in Severe Asthma Treated With Biotherapy","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-21","conditions":"Asthma","enrollment":105},{"nctId":"NCT04158050","phase":"","title":"Comparison of Biologicals in Treatment of Severe Asthma","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2018-01-01","conditions":"Asthma","enrollment":64},{"nctId":"NCT05932849","phase":"","title":"Benralizumab Patient Access Programme Study: Retrospective Study in UK Severe Asthma Centres","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-10-05","conditions":"Asthma","enrollment":276},{"nctId":"NCT04543409","phase":"PHASE3","title":"A Study of Benralizumab in Patients With Eosinophilic Esophagitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-09-22","conditions":"Eosinophilic Esophagitis","enrollment":211},{"nctId":"NCT06126692","phase":"","title":"3TR Asthma Biologics Cohort (ABC) Study","status":"RECRUITING","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2022-01-10","conditions":"Severe Asthma","enrollment":600},{"nctId":"NCT06024707","phase":"","title":"Fluctuation Analyses of Asthma Patients With Biologics Use","status":"UNKNOWN","sponsor":"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)","startDate":"2023-12","conditions":"Asthma","enrollment":48},{"nctId":"NCT04742504","phase":"","title":"Interaction Between Benralizumab and Basophils in Eosinophilic Asthma","status":"COMPLETED","sponsor":"Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","startDate":"2021-09-07","conditions":"Asthma; Eosinophilic","enrollment":20},{"nctId":"NCT04272463","phase":"","title":"ChAracterisation of ItaliaN Severe Uncontrolled Asthmatic patieNts Key Features When Receiving Benralizumab","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-03-13","conditions":"Severe Asthma","enrollment":217},{"nctId":"NCT04605094","phase":"PHASE2","title":"Efficacy and Safety Study of the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"AstraZeneca","startDate":"2020-11-12","conditions":"Atopic Dermatitis","enrollment":194},{"nctId":"NCT03976310","phase":"NA","title":"CT Air-trapping for the Early Identification of Benralizumab Responders Among Eosinophilic Asthma Patients","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2019-06-20","conditions":"Asthma","enrollment":59},{"nctId":"NCT05847452","phase":"","title":"Beyond the Eosinophil: Understanding the Impact of Eosinophil Depletion on T2 Inflammation. (BEUTI)","status":"UNKNOWN","sponsor":"Guy's and St Thomas' NHS Foundation Trust","startDate":"2023-05-22","conditions":"Asthma","enrollment":12},{"nctId":"NCT03557307","phase":"PHASE3","title":"Study to Evaluate Efficacy and Safety of Benralizumab in Reducing Oral Corticosteroid Use in Adult Patients With Severe Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-08-01","conditions":"Asthma","enrollment":598},{"nctId":"NCT04305405","phase":"PHASE3","title":"PK/PD and Long Term Safety Study of Benralizumab in Children With Severe Eosinophilic Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-11-21","conditions":"Severe Uncontrolled Asthma","enrollment":30},{"nctId":"NCT05180357","phase":"","title":"RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-11-23","conditions":"Severe Eosinophilic Asthma, Nasal Polyps","enrollment":273},{"nctId":"NCT05273359","phase":"PHASE2","title":"Immunological Basis for Benralizumab Activity in Chronic Obstructive Pulmonary Disease (COPD)","status":"UNKNOWN","sponsor":"Temple University","startDate":"2023-04","conditions":"Chronic Obstructive Pulmonary Disease (COPD)","enrollment":45},{"nctId":"NCT03470311","phase":"PHASE3","title":"Benralizumab in Patients With Inadequate Response to Anti-IL5 Monoclonal Antibody Therapies","status":"COMPLETED","sponsor":"McMaster University","startDate":"2018-04-26","conditions":"Severe Prednisone Dependent Eosinophilic Asthma","enrollment":20},{"nctId":"NCT04648839","phase":"","title":"Observational Retrospective Study on Clinical Outcomes of Patients Receiving Benralizumab in Spain.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-02-16","conditions":"Severe Asthma","enrollment":221},{"nctId":"NCT05228041","phase":"","title":"BIOlogics in Severe Nasal POlyposis SurvEy","status":"RECRUITING","sponsor":"University Hospital, Lille","startDate":"2022-02-10","conditions":"Chronic Rhinosinusitis With Nasal Polyps","enrollment":100},{"nctId":"NCT02130882","phase":"PHASE2, PHASE3","title":"Study to Evaluate Safety and Efficacy of Benralizumab in Subjects With Hypereosinophilic Syndrome","status":"UNKNOWN","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2014-05-19","conditions":"Respiratory System Agents, Anti-Asthmatic Agents, Hematologic Diseases","enrollment":20},{"nctId":"NCT03473977","phase":"PHASE2, PHASE3","title":"Benralizumab for Eosinophilic Gastritis (BEGS)","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2018-04-23","conditions":"Eosinophilic Gastritis or Gastroenteritis","enrollment":26},{"nctId":"NCT04108962","phase":"PHASE4","title":"Benralizumab in the Treatment of Patients With Severe Asthma With ABPA","status":"WITHDRAWN","sponsor":"Baylor Research Institute","startDate":"2019-12-23","conditions":"ABPA, Severe Asthma, Allergic Bronchopulmonary Aspergillosis","enrollment":""},{"nctId":"NCT04182802","phase":"","title":"MRI and Lung Function Measures of Benralizumab Response in Asthma","status":"WITHDRAWN","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2020-02-13","conditions":"Asthma","enrollment":""},{"nctId":"NCT05078281","phase":"","title":"Patients With Severe Eosinophilic Asthma Treated With Benralizumab","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2020-11-01","conditions":"Asthma; Eosinophilic","enrollment":60},{"nctId":"NCT03170271","phase":"PHASE3","title":"A Study of the Safety and Effectiveness of Benralizumab to Treat Patients With Severe Uncontrolled Asthma.","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-07-07","conditions":"Asthma","enrollment":660},{"nctId":"NCT03401229","phase":"PHASE3","title":"Efficacy and Safety Study of Benralizumab for Patients With Severe Nasal Polyposis","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2018-01-15","conditions":"Nasal Polyposis","enrollment":413},{"nctId":"NCT04617171","phase":"PHASE2","title":"Benralizumab Initiated During Severe Asthma Attack","status":"UNKNOWN","sponsor":"Singapore General Hospital","startDate":"2021-06-02","conditions":"Asthma Attack, Asthma","enrollment":128},{"nctId":"NCT04126499","phase":"","title":"Study to Characterise Patients Receiving Benralizumab in the Framework of an Individualized Access Program in Spain","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2020-01-13","conditions":"Severe Eosinophilic Asthma","enrollment":28},{"nctId":"NCT04665141","phase":"","title":"Similarities and Differences of Biological Therapies for Severe Asthma.","status":"UNKNOWN","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2021-04-07","conditions":"Asthma","enrollment":600},{"nctId":"NCT02808819","phase":"PHASE3","title":"A Safety Extension Study With Benralizumab for Asthmatic Adults on Inhaled Corticosteroid Plus Long-acting β2 Agonist","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-30","conditions":"Asthma","enrollment":447},{"nctId":"NCT04200326","phase":"","title":"Real-life First Dose Effect of Fasenra in Patients With Severe Uncontrolled Asthma","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-12-20","conditions":"Severe Uncontrolled Asthma","enrollment":5},{"nctId":"NCT03010436","phase":"PHASE2","title":"Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study","status":"UNKNOWN","sponsor":"National Jewish Health","startDate":"2017-04-15","conditions":"Asthma","enrollment":10},{"nctId":"NCT03450083","phase":"PHASE2","title":"Benralizumab Effect on Severe Chronic Rhinosinusitis With Eosinophilic Polyposis","status":"COMPLETED","sponsor":"Johns Hopkins University","startDate":"2017-07-01","conditions":"Chronic Rhinosinusitis (Diagnosis), Nasal Polyps, Eosinophilia","enrollment":33},{"nctId":"NCT02821416","phase":"PHASE3","title":"Study to Evaluate the Effect of Benralizumab on Allergen-Induced Inflammation in Mild, Atopic Asthmatics","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-10-11","conditions":"Asthma","enrollment":46},{"nctId":"NCT00768079","phase":"PHASE2","title":"A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563).","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2009-02-02","conditions":"Asthma","enrollment":110},{"nctId":"NCT04181190","phase":"","title":"Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients","status":"COMPLETED","sponsor":"Università degli Studi di Ferrara","startDate":"2019-10-11","conditions":"Asthma, Asthma; Eosinophilic","enrollment":130},{"nctId":"NCT04256772","phase":"","title":"Anti-IL5 and Other Biotherapies in Cystic Fibrosis","status":"UNKNOWN","sponsor":"University Hospital, Montpellier","startDate":"2019-07-01","conditions":"Cystic Fibrosis","enrollment":100},{"nctId":"NCT00783289","phase":"PHASE2","title":"A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma","status":"COMPLETED","sponsor":"MedImmune LLC","startDate":"2008-11-14","conditions":"Asthma","enrollment":35},{"nctId":"NCT02869438","phase":"PHASE3","title":"A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-11-09","conditions":"Asthma","enrollment":233},{"nctId":"NCT03928262","phase":"PHASE1","title":"Pharmacokinetic Study of Benralizumab in Healthy Chinese Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2019-04-02","conditions":"Healthy Subjects","enrollment":36},{"nctId":"NCT02258542","phase":"PHASE3","title":"A Safety Extension Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Asthmatic Adults and Adolescents on Inhaled Corticosteroid Plus LABA","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-11-19","conditions":"Asthma","enrollment":2133},{"nctId":"NCT03183024","phase":"PHASE4","title":"Treatment of Chronic Urticarial Unresponsive to H1-antihistamines With an Anti-IL5Ralpha Monoclonal Antibody","status":"COMPLETED","sponsor":"Jonathan A. Bernstein, MD","startDate":"2017-09-12","conditions":"Chronic Idiopathic Urticaria","enrollment":12},{"nctId":"NCT02968914","phase":"PHASE1","title":"Pharmacokinetic Comparability of Benralizumab Using Accessorized Pre-Filled Syringe or Autoinjector in Healthy Volunteers","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2017-01-04","conditions":"Asthma, Chronic Obstructive Pulmonary Disease","enrollment":180},{"nctId":"NCT02155660","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-06-25","conditions":"Moderate to Very Severe Chronic Obstructive Pulmonary Disease","enrollment":2255}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Benralizumab (Medi-563)","genericName":"Benralizumab (Medi-563)","companyName":"AstraZeneca","companyId":"astrazeneca","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Benralizumab is a monoclonal antibody that binds to the IL-5 receptor alpha on eosinophils and basophils, leading to their depletion and reduction of eosinophilic inflammation. Used for Moderate-to-severe eosinophilic asthma, Severe eosinophilic granulomatosis with polyangiitis (EGPA).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}